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Abstract
Introduction: Antimalarial resistance has led to a global policy of artemisinin-based combination therapy. Despite growing
resistance chloroquine (CQ) remained until recently the official first-line treatment for falciparum malaria in Pakistan, with
sulfadoxine-pyrimethamine (SP) second-line. Co-treatment with the gametocytocidal primaquine (PQ) is recommended for
transmission control in South Asia. The relative effect of artesunate (AS) or primaquine, as partner drugs, on clinical
outcomes and gametocyte carriage in this setting were unknown.
Methods: A single-blinded, randomized trial among Afghan refugees in Pakistan compared six treatment arms: CQ;
CQ+(single-dose)PQ; CQ+(3 d)AS; SP; SP+(single-dose)PQ, and SP+(3 d)AS. The objectives were to compare treatment failure
rates and effect on gametocyte carriage, of CQ or SP monotherapy against the respective combinations (PQ or AS). Outcomes
included trophozoite and gametocyte clearance (read by light microscopy), and clinical and parasitological failure.
Findings: A total of 308 (87%) patients completed the trial. Failure rates by day 28 were: CQ 55/68 (81%); CQ+AS 19/67
(28%), SP 4/41 (9.8%), SP+AS 1/41 (2.4%). The addition of PQ to CQ or SP did not affect failure rates (CQ+PQ 49/67 (73%)
failed; SP+PQ 5/33 (16%) failed). AS was superior to PQ at clearing gametocytes; gametocytes were seen on d7 in 85% of CQ,
40% of CQ+PQ, 21% of CQ+AS, 91% of SP, 76% of SP+PQ and 23% of SP+AS treated patients. PQ was more effective at
clearing older gametocyte infections whereas AS was more effective at preventing emergence of mature gametocytes,
except in cases that recrudesced.
Conclusions: CQ is no longer appropriate by itself or in combination. These findings influenced the replacement of CQ with
SP+AS for first-line treatment of uncomplicated falciparum malaria in the WHO Eastern Mediterranean Region. The threat of
SP resistance remains as SP monotherapy is still common. Three day AS was superior to single-dose PQ for reducing
gametocyte carriage.
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Introduction
Antimalarial drug resistance is an ongoing threat to malaria
control [1]. Despite widespread documented resistance, chloro-
quine remained widely used in Pakistan and Afghanistan for first
line treatment of falciparum malaria at the time of this study
(2000–2003) [2–4]. In many other parts of the world including
Pakistan and Afghanistan the antifolate drug sulfadoxine-
pyrimethamine (SP) is comparatively effective against falciparum
malaria in contrast to the situation in South East Asia and many
African settings. In Pakistan and Afghanistan transmission is
seasonal, strong immunity seldom develops, infected individuals
are symptomatic and it is thought that the majority seek
treatment [2,3,5]. These conditions expose the majority of
infections to antimalarial drugs and would be expected to exert
strong selection for resistance [6]. SP has a long plasma half-life
which may further contribute to selection. In such areas of low
seasonal transmission the operational effectiveness of SP before
resistance arises appears to be short [7]. Whilst current
effectiveness remains comparatively good in the region low level
in vivo resistance to SP has been demonstrated [5,8,9]. Wide-scale
adoption of effective SP based combinations, rather than SP
monotherapy, which was being considered as an option to
replace chloroquine at the time of the study, could delay the
selection of resistance and prolong the useful life of SP across the
subcontinent.
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In areas of low or medium endemicity co-treatment of infections
with a gametocytocidal drug may help to reduce transmission and
may be particularly important when considering strategies for
malaria elimination. In South Asia, the standard policy has been to
co-treat with a single dose of primaquine to reduce gametocyte
carriage. Primaquine is known to have poor efficacy as a direct
treatment but has repeatedly been shown to be highly gametocy-
tocidal [10–14]. Reduction in gametocyte carriage and infectivity to
mosquitoes after artesunate treatment is widely documented
[15,16]. It appears to be due to a combination of rapid clearance
of asexual stages, direct activity on immature gametocytes (either
killing them or preventing their maturation) and possibly reduction
in the infectivity of mature gametocytes [17,18]. Use of ACTs has
been shown to reduce transmission [19–23] and is recommended
for epidemic response [24], as too is primaquine [25]. There is
increasing interest in using primaquine with ACTs to accelerate
gametocyte clearance [14]. SP treatment of clinical infections can
lead to high gametocyte loads which persist for 10 days or more [15]
with latent gametocytaemia detected by PCR for up to a year [26].
A direct comparison of artesunate and primaquine on treatment
failure and gametocyte carriage has not been conducted before.
Many Afghan refugee communities in Pakistan have a history of
falciparum malaria and are prone to outbreaks [27–29]. A trial
examining the comparative efficacy of chloroquine and SP
combined with either artesunate or primaquine was therefore
carried out in refugee villages in North-western Pakistan.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol S1.
Study area and population
The study recruited patients from five Afghan refugee villages
within an 80 km radius of Peshawar, Khyber Province (formerly
North West Frontier Province), Pakistan. The 5 villages were
established in the early 1980s and each has a history of falciparum
transmission. Three (Adizai, Naguman and Yakka Ghund) are
situated on the banks of the Kabul river, and two (Mohammed
Khoja and Kotki) are situated to the south of Peshawar in Kohat
district. Malaria transmission is seasonal with vivax malaria
occurring from March to November and falciparum from July
to December.
Participants were Afghan refugees who were permanently resident
in the Pakistan villages. A minority might have acquired their
infections in Afghanistan, but admission criteria required 4–6 weeks
of follow-up which would have excluded the more regular travellers.
Study sites
The study was conducted through three sites with well-managed
clinics run by Non-Governmental Organisations (NGO) and
government agencies. Site 1 was Adizai village which also served
the population of nearby Naguman. Site 2 was Yakka Ghund
village. Site 3 was Kotki which also serviced Mohammed Khoja
village. Health staff from the NGO HealthNet TPO were
seconded to each clinic to manage the recruitment and follow-
up of patients.
The study took place over three malaria seasons from 2000 to
2003. In the first season only site 1 was used, in the second season
site 2 was added, and in the third season site 3 was added. The
stepped inclusion of sites resulted from unexpectedly low
recruitment rates at the first study site, and is summarized in
Table 1. An earlier in vivo survey across all refugee camps along the
length of the 1000 km North-South axis of Khyber Province
showed little heterogeneity in resistance frequency to chloroquine
and SP [30]. (Note that SP is the only drug name abbreviated
throughout the text. Abbreviations for chloroquine (CQ),
primaquine (PQ) and artesunate (AS) are used when referring to
specific study arms (e.g. CQ+PQ) but not at other points in the
text.)
Study design and procedures. Individuals presenting with
clinical symptoms and diagnosed microscopically with falciparum
malaria were referred to trial staff for further assessment. Inclusion
criteria were: over two years of age, not pregnant, P. falciparum
mono-infection, more than 1 asexual parasite per 10 fields, no
other serious disease, resident in the refugee village for the full
period of follow-up, no verbal report of antimalarial use during the
last 21 days, and no signs of severe malaria.
Individuals meeting the inclusion criteria and giving informed
consent were allocated using randomization tables stratified by age
and sex to the following treatment arms: chloroquine (CQ1)
(25 mg/kg) over 3 days; CQ (25 mg/kg) over 3 days plus
primaquine (PQ) (0.5 mg/kg) on the last day of treatment; CQ
(25 mg/kg) over 3 days plus artesunate (AS) (4 mg/kg per day)
over 3 days; sulfadoxine (25 mg/kg) and pyrimethamine
(1.25 mg/kg) (SP) on day 0; SP (25:1.25 mg/kg) plus PQ
(0.5 mg/kg) on day 0; SP (25:1.25 mg/kg) on day 0 plus AS
(4 mg/kg per day) over 3 days. The primaquine co-treatment
regimens were based on recommendations for use of primaquine
as a gametocytocide treatment for falciparum malaria [31]. On
treatment days when any specific arm did not require a partner
drug, a placebo was substituted.
Patients were not allocated to all six treatment arms at each site
(Table 1). During years two and three, at any one site, patients
were allocated to either one of the three SP treatment arms or one of
the three chloroquine treatment arms; only in year one were
patients allocated to all six treatment arms in the original site.
For each of the study sites patients were stratified by age and sex
and assigned consecutive patient numbers at enrolment. Treat-
ment groups were pre-assigned to patient numbers using simple
randomization lists generated using Excel (Microsoft Corp.,
Seattle, USA). The assignment of treatment group to patient
Table 1. Summary of treatment arms tested at each of the study sites over the three transmission seasons.
Study site
Transmission season (July–January) Site 1 (Adizai) Site 2 (Yakka Ghund) Site 3 (Kotki)
Season 1: 2000–2001 CQ, CQ+PQ, CQ+AS,
SP, SP+PQ, SP+AS
Season 2: 2001–2002 SP, SP+PQ, SP+AS CQ, CQ+PQ, CQ+AS
Season 3: 2002–2003 CQ, CQ+PQ, CQ+AS SP, SP+PQ, SP+AS CQ, CQ+PQ, CQ+AS
doi:10.1371/journal.pone.0028957.t001
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number was concealed until after enrolment. The random
allocation sequence was generated by two of the investigators
(KK, MR) neither of whom enrolled or assessed patients.
The brands and manufacturers/suppliers were: SP (Fansidar H,
Roche), chloroquine (Nivaquine H, Beacon), primaquine (IDA),
artesunate (Plasmotrim TM, Mepha). Although chloroquine
resistance was known to exist in the study area, chloroquine was
the first line treatment policy of the Government of Pakistan and
the UN refugee agency (UNHCR) at the time and was therefore
included.
The trial manager, who allocated the treatment arms and
administered treatment, was not blind to the study drugs and
allocations. Recruited patients, microscopists and health workers
were partially blinded; full blinding was not achieved given (i) the
appearance of the different drugs, and (ii) the different times of
follow up for the SP arms compared to the chloroquine arms.
Patients were given directly observed treatment (by the trial
manager), monitored for 30 minutes and re-dosed if vomiting
occurred. Health workers then recorded the other day 0
biomedical parameters.
Patients were asked to return on each day of treatment (days 0,
1, 2) and on days 3, 7, 14, 21 and 28 post treatment. Patients in the
three SP arms were also followed up on days 35 and 42 for
detection of late recrudescence [32]. On each day of follow up
thick and thin smears were taken, clinical symptoms recorded and
blood spots collected on Whatman No. 1 filter paper for parasite
typing and differentiation of recrudescent from new infections.
Haematocrits and blood spots were taken either on the day of
failure or on day 28. Patients not presenting at the clinic were
followed up at home. Criteria for withdrawal were reported
administration of additional anti-malarial drugs (protocol viola-
tion), emergence of any concomitant febrile illness that interfered
with outcome classification (including a non-falciparum malaria,
for which the withdrawn study patient would be given appropriate
first line treatment), parasitaemia still present on day 7, or signs of
severe malaria developing before completing the initial treatment
course.
Patients found to be parasitaemic on any day after day 3 were
treated with SP (the official second line treatment) or with SP and
mefloquine (Fansimef, Roche) for those whose initial treatment
was SP based. SP resistant parasites were sensitive to the
mefloquine component of Fansimef, which was used in lieu of
mefloquine monotherapy which was unavailable in the study area.
Those who developed severe malaria, severe anaemia or other
complications were referred to Khyber Hospital, Peshawar for
treatment.
Laboratory tests. Thick and thin blood smears were stained
with 2% Giemsa solution. All slides were read on the day of
collection by a microscopist based at each site. Differential
diagnosis of vivax and falciparum (trophozoites and gametocytes)
was by examination of thick and thin smears according to standard
microscopy methods [33]. Trophozoites and gametocytes were
counted against 200 white blood cells (WBC) from the thick blood
smear on the assumption of a WBC count of 8000/ml. A smear
was declared negative if no parasites were seen after examining
100 fields. Slides from sites 2 and 3 were re-examined for accuracy
by the site 1 microscopist. Comparison was made between the
parasite counts made by the three microscopists. The mean
variation in parasite count for trophozoites and gametocytes was
less than 5%. Owing to electricity supply deficiency, the
haematocrit microcentrifuge was only used at sites 1 and 3.
Outcome measures. Patients completed the trial if treatment
was administered fully and all follow-up appointments conducted,
or if they failed treatment on any day of follow-up. The primary
endpoint of the trial was any clinical or parasitological failure up to
day 28, although a subset of patients in the SP treatment arms was
also followed until day 42. Patient outcomes were classified under
the WHO parasitological classification system of sensitive (S) or
resistant (RI, RII, RIII) infections with those whose outcomes were
classified as S (sensitive) being treatment successes and those with
outcomes of RI, RII or RIII being classified as treatment failures
[34]. This classification system was still commonly used at the time
of the study and the ethical clearance for this study (received in
2000) was based on a protocol using this classification system.
Patients were also classified against the newer WHO treatment
outcome system [35,36]. Presenting the outcomes under both of
these systems allows better comparability with data past and
present [37]. For the WHO classification system standard
definitions were applied: adequate clinical and parasitological
response (ACPR), early treatment failure (ETF) or late treatment
failure (LTF) which incorporated standard definitions of late
clinical and parasitological response [35]. Those cases with ETF or
LTF were classified as treatment failures, and ACPR was classified
as treatment success if they completed the follow-up period.
Other parameters examined were time to fever resolution (with
fever defined as axillary temperature $37.5uC), asexual parasite
clearance, gametocyte clearance and gametocyte carriage on or
after day 7.
Molecular characterisation. PCR genotyping was con-
ducted on a subset of samples to distinguish recrudescent from new
infections using the protocol described by Brockman et al [38]. P.
falciparum genes msp-1, msp-2 and glurp were genotyped according to
polymorphisms present at variable loci on day 0 and day of failure.
Approximately 50% of cases were available for genotyping.
PCR corrected outcomes were applied as a secondary analysis
using redefined outcomes based on the number and frequency of
true recrudescent infections and reclassifying cases with new
infections as treatment successes, excluding those with indetermi-
nate outcomes or negative PCR results. PCR testing was
performed at the Shoklo Malaria Research Unit, Thailand.
We also conducted an analysis at the London School of Hygiene
and Tropical Medicine (LSHTM), UK, for known resistance-
associated mutations to chloroquine and antifolate drugs. Samples
collected at enrolment were tested for known mutations in the pfcrt,
pfmdr1, pfdhfr and pfdhps genes [39,40]. PCR and sequence specific
oligonucleotide probe assays were used to analyse nucleotide
polymorphisms at pfcrt codon 76, pfmdr1 codons 86 and 184, pfdhfr
codons 16, 51, 59 and 108 and pfdhps codons 436, 437, 581 and
613 [41].
Sample size and data analysis
The sample size required to detect a difference in treatment
failure or gametocyte carriage with 80% power and 95%
confidence (two-sided significance level for type 1 error of 0.05)
were calculated using the following predictions. In the chloroquine
arms (i) the estimated frequency of failure in chloroquine
monotherapy arm was 30% and in each of the combination arms
(CQ+PQ or CQ+AS) it was 10% or less; (ii) the estimated
proportion of gametocyte positive individuals after 7 days in the
chloroquine arm was 50% and in each of the combination arms it
was 25%. In the SP arms (i) the estimated frequency of failure in
the SP arm was 10% and in each of the combination arms
(SP+PQ or SP+AS) it was 1%; (ii) the estimated frequency of
gametocyte positive patients after 7 days in the SP arm was 50%
and in each combination arm it was 25%. The estimated samples
sizes were 64 per arm in the chloroquine arms and 121 per arm in
the SP arms. For gametocyte carriage the required sample sizes
were 65 per arm. The target sample sizes for the study were 65 for
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the chloroquine arms and 121 for the SP arms. To allow for 15%
loss to follow up the targets for recruitment were 76 for the
chloroquine arms and 142 for the SP arms.
The primary aims of the study were to evaluate: 1) the relative
efficacy of the combination drugs in providing parasite clearance
with no recrudescence compared to monotherapy, and 2) the
effect on gametocyte clearance. The secondary aim was to
determine the proportion of individuals in each arm with
classifiable treatment failure.
The primary outcome was the proportion of individuals in each
treatment group classified as a treatment failure during the 28 days
follow-up compared to the respective monotherapy. The odds of
treatment failure between each of the study groups at day 28 were
estimated after adjusting for potential confounders (age, sex,
parasitaemia, PCV, study site) using logistic regression analysis or
Mantel-Haenszel x2 test. Treatment failure was also analysed
using the definitions of ACPR and ETF or LTF, and
parasitological classifications using the S-R scale in addition to
the PCR corrected analysis [35]. Time to event data (time to
treatment failure) were analysed with Kaplan Meier survival
analysis.
For assessing potential effects on gametocyte carriage, the
primary outcome was the presence or absence of gametocytes on
day 7 with a secondary analysis examining the presence or absence
of gametocytes and the geometric mean gametocyte density on
each day of follow-up.
All data were entered in Microsoft Excel (1997) by one data
clerk and the database checked patient by patient against paper
records by a second data clerk. Analysis was performed using
STATA 10.0 (STATA Corp, College Station, TX, USA).
Ethics Statement
The study protocol was approved by the ethics committees of
the Pakistan Medical Research Council and LSHTM, UK. All
patients or their guardians gave written informed consent to
participate. The trial was registered under clinicaltrials.gov
[NCT00959517].
Table 2. Enrolment characteristics of the treatment groups.
Variable CQ CQ+PQ CQ+AS SP SP+PQ SP+AS
Number enrolled 76 76 74 45 40 44
Number evaluable at day 28 (%) 68 (89) 67 (88) 67 (91) 41 (91) 33 (82) 41 (93)
Age [median (IQR) years] 12 (8–18) 12 (8–20) 12 (8–20) 17 (9–27) 14 (7–25) 18.5 (9.5–30)
Percentage female 42 37 50 33 43 45
Weight [median (IQR) kg] 29 (20–47) 30 (20–53) 33 (20–45) 48 (25–58) 42 (22–55) 41 (21–57)
Temperature [mean (SD) uC] 37.3 (1.0) 37.5 (1.2) 37.4 (1.2) 37.5 (1.0) 37.5 (1.2) 37.5 (1.5)
Temperature $37.5uC on
presentation [n (%)]
33 (43) 34 (45) 34 (46) 21 (47) 17 (43) 23 (52)
PCV [mean (SD) % haematocrit]1 42.9 (9.7) 40.8 (3.9) 41.5 (4.3) 44.2 (7.7) 45.5 (6.9) 44.3 (5.1)
PCV,30% [n (%)]1 0 0 0 1 (2.2) 0 0
Asexual parasite density
[geometric mean (95% CI) per ml]
5161 (3536–7535) 5263 (3647–7595) 7366 (4972–10,915) 7600 (5185–11,140) 8091 (4236–15,454) 12,134 (7757–18,982)
Gametocyte positive [n (%)] 12 (15.8) 15 (19.7) 9 (12.2) 14 (31.1) 7 (17.5) 7 (15.9)
Gametocyte density [geometric
mean (95% CI) per ml]
1.3 (0.4–2.6) 1.7 (0.7–3.4) 0.6 (0.2–1.2) 4.1 (1.4–10.1) 1.6 (0.3–4.1) 1.2 (0.2–2.9)
Notes: (1) PCV was not recorded for all patients; a microcentrifuge was only available at one of the 3 clinics. For PCV percentages in the 6 treatment groups: CQ n=10;
CQ+PQ n= 19; CQ+AS n= 13; SP n = 19; SP+PQ n= 15, SP+AS n= 15.
doi:10.1371/journal.pone.0028957.t002
Figure 1. Trial profile.
doi:10.1371/journal.pone.0028957.g001
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Table 3. Clinical and parasitological failure rates at 28 days follow-up and for gametocytaemia at day 7.
Day 28 clinical or parasitological failure Day 7 gametocytaemia
No./Total (%) Odds Ratio (95% CI) P No./Total (%) Odds Ratio (95% CI) P
CQ 55/68 (81) Reference - 52/67 (78) Reference -
CQ+PQ 49/67 (73) 0.64 (0.29–1.4) 0.3 27/70 (39) 0.18 (0.09–0.4) ,0.001
CQ+AS 19/67 (28) 0.09 (0.04–0.2) ,0.001 12/72 (17) 0.06 (0.02–0.1) ,0.001
SP 4/41 (10) Reference - 37/43 (86.1) Reference -
SP+PQ 5/33 (16) 1.6 (0.41–6.7) 0.5 24/36 (66.7) 0.32 (0.10–1.0) 0.046
SP+AS 1/41 (2) 0.23 (0.02–2.2) 0.2 9/44 (20.5) 0.04 (0.01–0.1) ,0.001
doi:10.1371/journal.pone.0028957.t003
Figure 2. Kaplan Meier survival analysis showing cumulative probability of failure in CQ treatment groups (A) and SP treatment
groups (B).
doi:10.1371/journal.pone.0028957.g002
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Results
Recruitment and follow-up
A total of 355 cases of microscopically confirmed falciparum
malaria were enrolled into the study between July 2000 and
December 2002. Table 2 shows enrolment characteristics and
Figure 1 shows the trial profile. Patients were recruited to the
chloroquine arms in line with recruitment targets. Insufficient
numbers were recruited to the SP arms. This was due to
considerably lower than expected malaria cases occurring in these
locations during the study period (in contrast to the years leading
up to the study). Additional sites were added over the three-year
study period to increase recruitment but it was not possible to
continue the trial for longer because of resource constraints.
chloroquine arms met the recruitment targets because of the site
allocations and unexpected pattern of case loads in the third year.
Characteristics of patients recruited into the 3 chloroquine arms
were broadly similar, as were the three SP arms. The SP+AS arm
showed slightly higher asexual parasite densities on enrolment
than other groups (Table 2).
Of 355 patients enrolled, 38 (10.7%) were either withdrawn or
lost to follow up leaving 317 for possible inclusion (Figure 1). Of
these 292 (82%) were evaluable for parasitological outcomes
because 25 patients classified as RII parasitological failure did not
meet the definition of clinical failure, i.e. they did not have fever
on day 3. Likewise, 308 (87%) were evaluable for clinical outcomes
because 9 patients who had classifiable Early Treatment Failure
did not fit the definition for parasitological failures (they did not
reach day 7 of the trial). Of the 266 patients followed up for 42
days, 221 (83%) were evaluable for clinical and parasitological
outcomes. All treatments were well tolerated and no severe or
serious adverse events were recorded during the study.
Clinical Outcomes. The 28-day failure rate in the CQ and
CQ+PQ arms was 81% and 73% respectively (Table 3, Figure 2A).
The addition of artesunate improved the treatment response, with
a treatment failure rate of 27%. The failure rates in the SP groups
were 16% or less (Table 3) with the combination of SP+AS having
the lowest failure rate (1/41 [2.4%]). Neither SP+AS nor SP+PQ
arms were significantly different to the SP arm at the 28-day end
point (Figure 2B).
None of the potential confounding factors examined (age, sex,
parasitaemia, study site, PCV) were associated with treatment
outcome so adjustments were unnecessary in the final regression
analysis. Crude odds ratios are presented.
Clinical and parasitological outcomes are shown in Table 4.
Only 32/133 (24%) of the individuals who failed had fever on the
day of failure; the majority of ‘late treatment failures’ therefore fell
into the category of ‘late parasitological failure’. Some recent
history of fever may have gone unreported.
Trophozoite clearance time (days until negative smear) was
lowest for the artesunate combination arms. Addition of
primaquine to either chloroquine or SP did not appear to affect
clearance times. Clearance times for each arm (median (inter-
quartile range)) were: CQ, 3 days (2–7); CQ+PQ, 3 days (2–7);
Table 4. Clinical and parasitological outcomes after 28 days follow-up: n (%).
CQ CQ+PQ CQ+AS SP SP+PQ SP+AS
Clinical outcomes N= 56 N=58 N= 67 N= 41 N= 30 N= 40
Adequate clinical response 13 (23) 18 (31) 48 (72) 37 (90) 28 (93) 40 (100)
Early treatment failure 9 (16) 7 (12) 0 1 (2) 1 (3) 0
Late clinical failure 2 (4) 4 (7) 1 (2) 0 0 0
Late Parasitological Failure 32 (57) 35 (50) 18 (26) 3 (7) 1 (3) 0
Parasitological outcomes N= 63 N=65 N= 67 N= 40 N= 32 N= 41
S 13 (21) 18 (28) 48 (72) 37 (93) 28 (88) 40 (98)
RI 35 (56) 33 (51) 19 (28) 3 (7) 1 (3) 0
RII 13 (21) 11 (16.9) 0 0 3 (9) 1 (2)
RIII 2 (3) 3 (5) 0 0 0 0
doi:10.1371/journal.pone.0028957.t004
Table 5. Outcomes of PCR analysis, and projected adjusted failure rates by treatment group excluding indeterminate results.
PCR Results [n (%)] Failure rates [n/N (%)]
Reinfection Recrudescent Negative Total in vivo 1 PCR adjusted 2
CQ 6 (21) 20 (69) 3 (10) 29 55/68 (81) 42/68 (62)
CQ+PQ 4 (21) 11 (58) 4 (21) 19 49/67 (73) 36/67 (54)
CQ+AS 7 (64) 3 (27) 1 (9) 11 19/67 (28) 6/67 (9)
SP 0 2 (100) 0 2 4/41 (10) 4/41 (10)
SP+PQ 0 2 (100) 0 2 5/33 (16) 5/33 (16)
SP+AS - - - 0 1/41 (2) 1/41 (2)
Notes: (1) Taken from Table 3 for 28 day failures; (2) Adjusted by the ratio of PCR recrudescent to PCR re-infected cases to estimate number of true recrudescent cases
among the observed in vivo failures.
doi:10.1371/journal.pone.0028957.t005
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CQ+AS, 2 days (1–2); SP, 2 days (2–3); SP+PQ, 2 days (1.5–3);
SP+AS, 1 day (1–2).
Of the 133 failures, 79 (47%) matched pairs were available for
PCR evaluation of MSP-1, MSP-2 and GLURP. Matched pairs
were collected on day 0 and on the day of failure. Outcomes of the
PCR are shown in Table 5, which excludes those with
indeterminate results. Most re-infections took place at one site
(Site 3, Yakka Ghund) where malaria transmission was higher than
in the other villages. Treatment outcomes were reclassified for
those failures where matched pairs were available and used to give
adjusted failure rates for the sample (Table 5). Although the
number of failures in the chloroquine arms was reduced by the
correction, the failure rates remained high at .50% for
chloroquine monotherapy. The PCR adjusted treatment failure
rate of the CQ+AS combination (9%) was considerably lower that
the in vivo rate (28%).
In the subset of patients followed-up for 42 days, recrudescence
between day 28 and 42 was rare: only 8/317 (2.5%) of individuals
classified as adequate clinical and parasitological response (ACPR)
or sensitive (S) at day 28 went on to fail by day 42 (1 in the CQ
arm, 2 in the CQ+PQ arm, 3 in the CQ+AS arm, 1 in the SP arm
and 1 in the SP+PQ arm). Failure rates at day 42 were therefore
similar to day 28. The failures between 28-day and 42-day rates
were not corrected by PCR and hence could have resulted from
new infections.
Molecular outcomes. Molecular analysis of drug resistance-
associated alleles was conducted on samples taken on day 0
(Table 6). The major marker of chloroquine resistance, pfcrt-76T,
was fixed at 100%. Mutations in pfmdr1 are known to modulate
resistance to quinoline and other drugs. The prevalence of
chloroquine-resistance associated allele pfmdr1-86Y was 13.6% in
this sample. Mutations associated with pyrimethamine resistance
(on the pfdhfr gene) were seen frequently; 108 N was found in all
but one of 74 typable samples (98.6%) and 59R occurred in 66/76
(86.8%) samples. However, 51I was only detected in 5/75 (6.7%)
samples. Therefore pfdhfr ‘double mutants’ were common (at
codons 108+59) but ‘triple mutants’ were rare. Interestingly, we
observed one sample with the pfdhfr mutations 16V+108T. These
are reportedly selected by the antifolate drug cycloguanil, rather
than pyrimethamine [42]. No mutations on the dhps gene were
seen. These PCR results broadly match what would be expected
from the clinical outcomes. The pfdhr/pfdhps mutation profile
suggests that the parasites would be killed by a full therapeutic
dose of SP, but that some tolerance to lower doses existed.
Effect on Gametocytes
The addition of artesunate or primaquine to chloroquine or SP
reduced gametocyte carriage on day 7 (Table 3). Combining
chloroquine or SP with artesunate succeeded in eliminating
gametocytaemia from more individuals by day 7 compared to
monotherapy or co-treatment with a single-dose of primaquine.
Figure 3 shows the proportion of individuals with patent
gametocytaemia over 28 days of follow-up. In the chloroquine and
SP arms, gametocyte carriage persisted at day 28 in .30% of
individuals in the CQ arm and .70% of individuals in the SP
arm. The addition of primaquine reduced gametocyte carriage;
the effect was more pronounced with chloroquine than with SP.
The proportion of gametocytaemic individuals was lowest in the
artesunate arms and the difference was evident within two days of
the start of treatment. Peak gametocyte densities occurred 7 days
after the start of treatment (Figure 4). Gametocyte density was
higher after SP than after chloroquine treatment. Both primaquine
and artesunate reduced density to low levels by day 7.
Most patients did not have gametocytaemia on day 0 (291/355
(82.0%) had no gametocytes on day 0). However, the presence or
absence of sexual stage parasites on day 0 was an important
explanatory variable in the secondary analysis; patients who
presented with gametocytes on day 0 were more likely to be
gametocytaemic on day 7 than individuals who were not
gametocytaemic on day 0 regardless of treatment group (Mantel-
Haenszel OR: 3.5 [95%CI: 2.0–6.4], p,0.001). We therefore
conducted further analysis comparing those who presented with
gametocytes on day 0 and those who did not.
The artesunate treatments were more effective at preventing the
emergence of gametocytaemia between day 0 and 7 than in
removing established gametocytaemia already present on day 0
(Table 7). For example, among the CQ+AS group who did have
patent gametocytaemia on day 0, 8/9 were still gametocytaemic
on day 7 after treatment. This was not significantly different from
the proportion gametocytaemic on day 7 (11/12) after treatment
with chloroquine monotherapy (Fisher’s exact test p = 1.0). By
contrast, in the chloroquine arms of the patients who did not have
patent gametocytaemia on day 0, only 11% (7/63) were
gametocytaemic on day 7 when treated with CQ+AS as compared
to 47/56 (84%) among those treated with chloroquine monother-
apy (x2 p,0.001). Similar trends were evident in the SP arms
treated with artesunate; prevalence of gametocytaemia on day 7
was significantly lower in the SP+AS group that was not
gametocytaemic on day 0 than in the group that was (Fisher’s
exact test p,0.001). This indicates that artesunate is less active
against older gametocytes than against those newly emerged or
immature forms that are not yet emerged. Primaquine showed no
such trend: the proportion of patients gametocytaemic on day 7
was not significantly different for patients who were or were not
gametocytaemic on day 0. Primaquine therefore appears to be
active against gametocytes of all ages.
Primaquine was more effective at controlling gametocytaemia
when combined with CQ than with SP, regardless of whether
individuals were gametocytaemic at the start of treatment (MH-
Table 6. Drug resistance alleles in a sub-set collected at
enrolment.
Locus Allele Number (%)
Pfcrt 76 K 0
76 T 63 (100)
Pfmdr1 86 N 76 (86)
86 Y 12 (14)
184 Y 22 (27)
184 F 60 (73)
DHFR 16 A 76 (99)
16 V 1 (1)
50/51 CN1 70 (93)
50/51 C1 5 (7)
59 C 10 (13)
59 R 66 (67)
108 N 73 (99)
108 T 1 (1)
DHPS 436/437 SA 43 (100)
581 A 41 (100)
613 A 43 (100)
doi:10.1371/journal.pone.0028957.t006
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OR=0.22, P= 0.001) (Table 7). By contrast, artesunate seemed as
effective when combined with chloroquine as it was when combined
with SP (MH-OR=1.04, P= 0.83). Though, as discussed, artesu-
nate was more effective at preventing development of patent
gametocytaemia than in clearing existing gametocytaemia. Artesu-
nate was better than primaquine at preventing patent gametocy-
taemia among those that were not gametocytaemic at day 0
enrolment (CQ: OR=0.30, P,0.001; SP: OR=0.18, P,0.001).
Using the presence of gametocytes on day 7 as the secondary
endpoint, adjusted for the presence of gametocytes at day 0, both
primaquine and artesunate with chloroquine or SP were more
effective than their respective monotherapies at reducing the
presence of gametocytes (Table 8).
Compared to monotherapy with chloroquine or SP, co-
treatment with artesunate was negatively associated with having
gametocytes on day 28 whether the accompanying drug was
chloroquine or SP (Table 8). The presence of gametocytes on day
0 was not associated with the presence of gametocytes on day 28
(MH-OR, adjusted for treatment arm: 1.0, p = 1.0) suggesting that
older gametocytes had cleared by day 28, regardless of treatment.
Figure 3. Percentage of patients (+CI) carrying gametocytes on specified days after treatment in CQ (A) and SP (B) treatment arms.
doi:10.1371/journal.pone.0028957.g003
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Discussion
The present study was designed to inform decision-making at
several levels: to guide UNHCR on appropriate treatment in the
Afghan refugee communities in Pakistan, to build evidence for
national treatment policy in the Pakistan Directorate of Malaria
Control and in the Afghanistan Ministry of Public Health, to guide
the WHO Eastern Mediterranean Region Office (EMRO) on
regional treatment recommendations, and to build evidence for
international epidemic response guidelines. The findings of this
study, when presented at an inter-country meeting of national
malaria control managers coordinated by WHO/EMRO in 2004,
contributed to a shift in policy from chloroquine monotherapy to
ACT in South and West Asia [43], influencing the defining of
Figure 4. Geometric mean gametocyte density (+CI) after treatment in chloroquine (A) and SP treatment arms (B). Note the different
scales on the Y-axis. Where the CI bars are absent, only 1 patient had gametocytes.
doi:10.1371/journal.pone.0028957.g004
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SP+AS as the first line treatment of choice for the WHO Eastern
Mediterranean Region. India is the latest neighbouring country to
adopt SP+AS as first line treatment with the support of WHO
[37]. The SP+AS combination is also effective against vivax
malaria [44], although not as an approved treatment.
SP monotherapy was effective in the study population, with
treatment failure rates remaining in the 5–10% range, similar to
that seen in other studies in the region [5,8,45]. Molecular studies
in the region show that genetic markers for SP resistance are still at
low levels in the parasite population [46,47]. However, the South
East Asian experience of rapid rise in SP resistance in settings of
similar endemicity [7] points to SP resistance spreading rapidly if
ACT policy is not implemented rigorously in both public and
private sectors across the region [37].
The complete failure of chloroquine (which at the time of the
study remained the officially sanctioned first line treatment)
convinced policy makers of the need to redefine treatment
practices in South Asia. The new data demonstrated higher levels
of resistance than in previous studies dating back to the 1980s and
1990s [2,3,5,48,49] and emphasised the need for change to
national treatment guidelines. The addition of artesunate to
chloroquine did reduce treatment failure rates, but if this regimen
was used as policy it would, in effect, constitute artesunate
monotherapy in the majority of infections and accelerate the
development of artesunate tolerance, as reported in South East
Asia [50].
A constraint on the study design was that not all 6 arms could be
included at each of the three study sites. Site is therefore a
potential confounding covariate that cannot be fully controlled for
in the data analysis. Differences in transmission could, for
example, affect the risk of re-infection between sites but this was
corrected for by the PCR analysis. At each site in any one year
each triplet of treatment arms (all the SP arms or all the
chloroquine arms) were examined at the same time, and it is
comparisons within these triplets which are of greatest interest.
The study did not complete its target sample size for the SP arms
because of low recruitment rates.
PCR corrected outcomes were not attainable for all failures, and
higher numbers of patients were reinfected at one site where only
the chloroquine arms were being tested. Low rates of transmission
at the other sites make it unlikely that failing cases were due to
reinfection. The secondary analysis with PCR-corrected outcomes
did not change the overall conclusions on the suitability of the
combinations for revised treatment policy.
Treatment with either the clinically effective SP monotherapy
or the failing chloroquine monotherapy resulted in persistence of
gametocytaemia into the second and third weeks in the majority of
individuals. This effect was more evident for SP than for
chloroquine, SP being well known for high rates of gametocyte
carriage post treatment [32]. This contrasts with situations of low-
frequency chloroquine resistance where the proportion of
gametocytaemic patients post treatment also tends to be lower
[16,51].
The effect of artemisinin derivatives on reducing gametocyte
carriage is already documented [16,52]. Artesunate also proved
highly effective in reducing the prevalence of gametocytaemia in
the present study. Regimens combining artesunate with chloro-
quine or SP saw marked reductions in gametocyte carriage and
few cases had persisting gametocytaemia. As demonstrated with
SP+AS in The Gambia [16] the SP+AS and CQ+AS combina-
Table 7. Numbers and percentages of individuals with gametocytes on day 7 post treatment.
No (%) parasitaemic on day 7
Amongst those who had gametocytes on day 0 Amongst those who did not have gametocytes on day 0
CQ 11/12 (91.7%) a, 1 47/56 (83.9%) a, 1
CQ+PQ 7/14 (50%) b, 1 21/56 (37.5%) b, 1
CQ+AS 8/9(88.9%) a, 1 7/63(11.1%) c, 2
SP 14/14 (100%) a, 1 25/29 (86.2%) a, 1
SP+PQ 5/7 (71.4%) b, 1 23/30 (76.7%) a, 1
SP+AS 5/7 (71.4%) b, 1 5/37 (13.5) b, 2
Chloroquine or SP treatments in the same column that share the same superscript letter are not significantly different. Treatments in the same row that share the same
numeric superscript are not significantly different.
doi:10.1371/journal.pone.0028957.t007
Table 8. Effect of treatment on gametocyte carriage at day 7 and day 28, for those patients who were gametocytaemic on
enrolment.
AOR for presence of gametocytes on day 7, (95% CI), p-value 1 AOR for presence of gametocytes on day 28, (95% CI), p-value 1
CQ Reference Reference
CQ+PQ 0.15 (0.07–0.34), p,0.001 0.42 (0.08–2.2), p = 0.3
CQ+AS 0.05 (0.02–0.12), p,0.001 0.04 (0.004–0.39), p = 0.006
SP Reference Reference
SP+PQ 0.37 (0.12–1.16), p = 0.09 0.14 (0.05–0.4), p,0.001
SP+AS 0.04 (0.01–0.13), p,0.001 0.02 (0.005–0.1), p,0.001
Notes: (1) AOR: Odds ratios using logistic regression analysis adjusted for presence of gametocytes on day 0 (CQ and SP arms analysed separately).
doi:10.1371/journal.pone.0028957.t008
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tions appear to have limited activity against mature circulating
gametocytes [53]. Co-treatment with a single dose of primaquine
was more effective against older gametocyte infections. Both
primaquine and, more markedly, artesunate reduced the odds of
persisting gametocytes from that seen post treatment with either
chloroquine or SP monotherapy.
Primaquine is more rapidly excreted than artesunate and this
may account for the fact that the single dose of primaquine used in
this study had a lower impact on gametocyte carriage than the
artesunate regimens. The usefulness of primaquine as a gameto-
cytocidal treatment may be improved by administering it after the
ACT course [14,54].
In our study, a key factor in the clearance of gametocytes was
the presence or absence of gametocytes on day 0. Those who
presented with gametocytes were more likely to have gametocytes
on day 7, an effect which was independent of the treatment given.
Although the majority of patients (80%) presented without
gametocytaemia, artesunate appeared to be less active against
these older parasites whereas primaquine appeared to be effective
against all ages. The proportion presenting with gametocytes may
vary according to background transmission levels. If gametocytes
persist after treatment with ACTs, the effect on transmission in
areas where a high proportion of cases present with gametocytes
may prove suboptimal and justify the simultaneous use of
primaquine.
Primaquine is more rapidly excreted than artesunate and this
may account for the fact that the single dose of primaquine used in
this study had a lower impact on gametocyte carriage than the
artesunate regimens. The usefulness of primaquine as a gameto-
cytocidal treatment may be improved by administering it after the
ACT [14,54].
For treatment policy to have a major impact on transmission
several criteria need to be met: i) transmission is low to moderate;
ii) the majority of people use public health rather than private
facilities, or effective private sector interventions ensure adherence
to policy; iii) public health facilities correctly prescribe the
approved regimen, and iv) patients take the full course. These
conditions are largely met in the refugee villages of Pakistan. The
region is characterized by low endemicity and low immunity, well
supported health care facilities are available in the Afghan refugee
villages, and diagnosis of malaria to species level is maintained to a
high standard [28]. The health facilities are well utilized by the
Afghan refugees and Pakistanis living nearby. The effect of this
policy is evident in the refugee populations: since 2005 falciparum
malaria has virtually disappeared in all but a handful of the
refugee villages [International Rescue Committee, Final Report,
unpublished]. This reduction is attributed to prompt and accurate
diagnosis and wider access to ACTs as prevention interventions
were minimal.
The operational data from this region and elsewhere suggest
that drugs showing faster gametocyte clearance in clinical trials do
help to reduce transmission [20–23]. However, it is also important
to note the results of recent research which suggest that drawing
conclusions about the potential impact on transmission is not
straightforward, for the following reasons:
i. The effect of drugs on gametocyte carriage cannot be fully
determined if only standard light microscopy (LM) is used.
Research in the last decade shows that LM gives starkly
different indications of gametocyte prevalence and densities
compared to other techniques [55] and that sub-microscopic
levels of gametocytes likely play an important role in
transmission, perhaps particularly in low transmission
settings [56].
ii. Gametocytes that are readily identified in blood following
treatment may or may not be viable. Gametocytes may not
be infective to mosquitoes either because they are recently
emerged (naturally, gametocytes are not infectious to
mosquitoes in the first 1–2 d of emergence [57]) or because
the effect of the drug regimens have rendered them ‘sterile’
[58].
iii. It is unclear how the density of gametocytes in the blood links
to potential for transmission success to blood feeding
mosquitoes. Bousema & Drakeley [57] summarise the
available data from membrane feeding studies showing that
whilst there is an overall correlation, the variations within it
are confusing; high density gametocytaemia can lead to
minimal mosquito infection and very low densities lead to
reasonable rates of infection.
iv. Even if solid data show that a particular drug does reduce the
number of gametocytes which successfully infect, and lead to
infectious, mosquitoes; the effect of this on malaria
transmission cannot be stated with certainty. This effect
would depend on what proportion of the gametocyte
reservoir these patients would otherwise make up [56].
The comparative performance of artesunate and primaquine on
gametocyte carriage in this study did not influence policy. The
decision to use SP+AS was based on treatment efficacy and the
need to protect against SP resistance through the use of an ACT
combination. The fact that SP+AS led to reduced gametocyte
carriage compared to the previous policy of chloroquine month-
erapy was reassuring, and raised the possibility of the regimen
reducing transmission too.
SP+AS is now the first line treatment policy in Pakistan, Iran,
Afghanistan and India. The continuing collection of molecular
data on SP resistance in this region will be vital, given that the
treatment efficacy of artesunate could mask the emergence of SP
resistance by acting alone to provide a degree of clinical cure in the
presence of a failing companion drug [59]. This risk could be
reduced by introduction of a co-blister of SP plus artesunate.
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